Edgewise The price target of therapeutic prices was reduced to $ 40

Wedbush Analyst Laura Chico lowered the firm Price target In Edgewise Therapistics (Ewtx) Up to $ 40 to $ 35 and keeps a superior rating in stocks. Edgewise said the Canyon’s data was not enough to support a document accelerated to support the Becker muscle dystrophy, but additional avenues will be investigated and informed investors in the research record. Wedbush sees several unanswered questions to love the DMD as a patient’s population.

Was first published Tort – Real-time mode, the last source for financial news moving in the market. Try it now >>

See Todranks to the best working shares today >>

Read more in EWTX:

Refusal and disclosureReport an issue